abstract |
The present invention relates to a Gremlin-1 antibody that inhibits Gremlin-1 in a manner independent of bone morphogenetic protein (BMP) or vascular endothelial growth factor receptor-2 (VEGFR-2), thus providing the effect of treating cancer. The antibody of the present invention inhibits cell migration, cell invasion and cell proliferation which are dependent on Gremlin-1, and therefore, can be effectively used in treating cancer or immune disease. |